1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Sickle Cell Disease (SCD): new trials by email Literature Review of Sickle Cell Disease (SCD) trials Research Report on Sickle Cell Disease (SCD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glutamine Early Start in Children With SCD Younger Than Five Glutamine, Standard of Care (SOC) - Sickle Cell Disease (SCD) | Phase 3 | Not yet recruiting | Ain Shams University | 70 | 2026-12-01 | 2026-11-17 |
| Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD) | Phase 2 / Phase 3 | Recruiting | Yves Pastore | 29 | 2026-02-03 | 2026-08-21 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Crizanlizumab (SEG101), Placebo - Sickle Cell Disease (SCD) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 253 | 2019-07-26 | 2026-10-14 |
Anemia, Sickle Cell (3) · Hematologic Diseases (1) · Sickle Cell Trait (1) · Vaso-Occlusive Crises (1)
Anemia (3) · Anemia, Hemolytic (3) · Anemia, Hemolytic, Congenital (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Hemoglobinopathies (3) · Hematologic Diseases (2)
Glutamine (1) · Standard of Care (1) · crizanlizumab (1)
Ain Shams University (1) · Novartis Pharmaceuticals (1) · Yves Pastore (1)
Canada (2) · Belgium (1) · Brazil (1) · Colombia (1) · Egypt (1) · Finland (1) · France (1) · Germany (1) · Ghana (1) · Greece (1) · India (1) · Italy (1) · Jordan (1) · Lebanon (1) · Netherlands (1)
2017 (1)